Mechanopharmacology: The Hidden Role of Physical Forces in Drug Delivery

1. Introduction/Overview

The traditional paradigm of pharmacology has predominantly focused on the biochemical interactions between drug molecules and their biological targets. However, a more comprehensive understanding of drug action necessitates the integration of physical principles. Mechanopharmacology emerges as an interdisciplinary field that investigates how mechanical forces and the physical properties of tissues and cells govern the delivery, distribution, and efficacy of pharmaceutical agents. This perspective acknowledges that the body is not a static biochemical milieu but a dynamic mechanical environment where forces such as pressure, shear stress, strain, and stiffness play critical roles.

The clinical relevance of mechanopharmacology is profound, offering explanations for variable drug responses in different physiological and pathological states. For instance, the altered hemodynamics in heart failure, the increased interstitial pressure in solid tumors, and the variable stiffness of fibrotic liver tissue all create distinct mechanical landscapes that directly influence how a drug reaches its site of action. Ignoring these factors can lead to suboptimal dosing, therapeutic failure, or unexpected toxicity. By elucidating the hidden role of physical forces, mechanopharmacology provides a framework for designing more effective and targeted therapeutic strategies, particularly for diseases characterized by significant mechanical alterations.

Learning Objectives

• Define mechanopharmacology and distinguish its scope from classical biochemical pharmacology.
• Explain the fundamental physical forces (e.g., interstitial fluid pressure, shear stress, solid stress) that influence drug pharmacokinetics, particularly distribution.
• Describe the concept of mechanotransduction and how cellular responses to physical cues can alter drug pharmacodynamics and therapeutic targets.
• Analyze how pathological changes in tissue mechanics, such as in solid tumors or fibrotic diseases, create barriers to effective drug delivery.
• Evaluate emerging therapeutic strategies, including nanomedicine and physical force-based delivery systems, that are informed by mechanopharmacological principles.

2. Classification

Mechanopharmacology does not classify drugs by chemical structure or receptor target in the conventional sense. Instead, its classification is based on the nature of the physical forces involved and the therapeutic strategies designed to exploit or overcome them. This framework can be organized according to the primary mechanical barrier or force being addressed.

Classification by Targeted Physical Force or Barrier

3. Mechanism of Action

The mechanisms underpinning mechanopharmacology operate at multiple scales, from the macroscopic forces governing bulk fluid flow to the nanoscale forces sensed by individual cells. These mechanisms can be broadly divided into those affecting pharmacokinetics (drug delivery) and those affecting pharmacodynamics (drug action).

Macroscopic and Tissue-Level Mechanisms

At the tissue level, physical forces create barriers or conduits for drug transport. The primary forces involved include:

• Interstitial Fluid Pressure (IFP): In healthy tissues, IFP is slightly subatmospheric, promoting convective flow from capillaries into the interstitium. In pathologies like solid tumors, IFP is markedly elevated due to leaky vasculature, poor lymphatic drainage, and ECM compression. This high IFP opposes the pressure gradient needed for drug extravasation, creating a functional barrier. Drugs must diffuse against this pressure, which is inefficient for large molecules and nanoparticles.
• Solid Stress: This refers to the mechanical stress exerted by and within the ECM and cells. In growing tumors or fibrotic tissues, proliferating cells and cross-linked ECM generate compressive and tensile solid stresses that collapse blood and lymphatic vessels, further impairing delivery. Solid stress also directly compresses cells, altering their phenotype.
• Blood Flow and Shear Stress: The rate and pattern of blood flow (laminar vs. turbulent) determine the concentration of drug presented to the vascular wall (margination) and the wall shear stress. High shear stress in arteries can influence endothelial cell permeability and the adhesion of targeted drug carriers. In regions of disturbed flow, such as atherosclerotic plaques, altered shear profiles can be exploited for targeted delivery.

Cellular and Molecular Mechanisms: Mechanotransduction

Mechanotransduction is the process by which cells convert mechanical stimuli into biochemical signals. This process fundamentally alters the cellular context in which a drug acts.

• Mechanosensing: Cells sense physical forces through integrins (linking the ECM to the cytoskeleton), cadherins (cell-cell adhesion), ion channels (e.g., Piezo channels), and G-protein coupled receptors. The stiffness of the underlying substrate (ECM) is a key cue.
• Signal Transduction: Force application leads to activation of signaling cascades. Key pathways include:
  • Focal Adhesion Kinase (FAK) and Src: Integrin clustering activates FAK/Src, regulating cell survival, proliferation, and migration.
  • Rho GTPase Pathway: Regulates actin cytoskeleton dynamics, generating contractile force and influencing cell shape and stiffness.
  • Hippo Pathway (YAP/TAZ): Mechanical cues regulate the nucleocytoplasmic shuttling of transcriptional co-activators YAP and TAZ. On stiff matrices, YAP/TAZ translocate to the nucleus and drive pro-proliferative and pro-fibrotic gene expression.
• Altered Drug Response: Activation of these pathways can change a cell’s state, making it more resistant or sensitive to drugs. For example, increased matrix stiffness and subsequent YAP activation in cancer cells is associated with chemotherapy resistance and a stem-like phenotype. Therefore, a drug’s pharmacodynamic effect is not solely a function of its concentration and receptor affinity, but also of the mechanical state of the target cell and its associated signaling activity.

4. Pharmacokinetics

The influence of physical forces is most pronounced during the distribution phase of pharmacokinetics, though effects on absorption and excretion are also recognized. The standard parameters of volume of distribution (V_d) and clearance are, in reality, mechano-dependent variables.

Absorption

For systemically administered drugs, absorption into the circulation may be influenced by local mechanics. Intramuscular injection efficacy can depend on muscle movement and local pressure. Transdermal delivery is hindered by the mechanical barrier of the stratum corneum, and techniques like microneedles or sonophoresis apply physical force to overcome it. Oral absorption of some compounds may be modulated by gut peristalsis and shear forces.

Distribution

Distribution is the pharmacokinetic phase most governed by mechanopharmacology. The key equation describing drug distribution into a tissue is an extension of Fick’s laws and Starling’s principle, incorporating both diffusion and convection:

J_s = J_diffusion + J_{convection = -D (dC/dx) + C (1-σ) Jv}

Where J_s is solute flux, D is diffusion coefficient, dC/dx is concentration gradient, σ is reflection coefficient, and J_v is volumetric fluid flux. J_v is driven by the difference between capillary pressure (P_c) and interstitial fluid pressure (P_if), and the colloid osmotic pressures. In tumors, P_if ≈ P_c, nullifying the convective term (J_v → 0), leaving slow diffusion as the only transport mechanism. This explains the poor distribution of monoclonal antibodies and nanomedicines in many solid tumors despite their theoretical targeting.

The apparent volume of distribution for a drug in a given tissue is not fixed but can contract or expand based on changes in perfusion pressure, vascular permeability, and interstitial pressure. For instance, in decompensated heart failure with high central venous pressure, the distribution of fluid-phase markers and certain drugs into peripheral tissues may be reduced.

Metabolism and Excretion

Physical forces can indirectly affect metabolism and excretion. Altered blood flow to the liver (e.g., in cirrhosis with portal hypertension) or kidneys (e.g., in renal artery stenosis) changes the rate of drug presentation to these eliminating organs, affecting intrinsic clearance. Shear stress on hepatocytes and endothelial cells in the liver sinusoids can modulate the expression of cytochrome P450 enzymes. Mechanical compression of the biliary tree or ureters can impede the excretion of drugs eliminated via bile or urine.

Pharmacokinetic Parameters in Altered Mechanical States

5. Therapeutic Uses/Clinical Applications

The principles of mechanopharmacology are not yet applied as discrete “mechanopharmaceutical” agents in clinical practice, but they inform the use and development of numerous existing and emerging therapies.

Approved Indications and Mechanopharmacological Rationale

• Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®): This formulation exploits the Enhanced Permeability and Retention (EPR) effect, a mechanopharmacological phenomenon where the leaky vasculature and poor lymphatic drainage in tumors lead to passive accumulation of nanoparticles. The PEG coating reduces opsonization, prolonging circulation time to allow for this accumulation.
• Hyaluronidase (PEGPH20, investigational): An enzyme that degrades hyaluronan, a major component of the ECM in pancreatic ductal adenocarcinoma. By breaking down this viscous matrix, hyaluronidase reduces solid stress and interstitial fluid pressure, decompressing blood vessels and improving the distribution of co-administered chemotherapy (e.g., gemcitabine, nab-paclitaxel).
• Angiotensin Receptor Blockers (ARBs) & ACE Inhibitors in Oncology: Beyond their antihypertensive effects, these drugs may transiently normalize tumor vasculature by reducing angiogenic signaling. This “vascular normalization” can lower interstitial fluid pressure, improve perfusion, and enhance the delivery of concurrently administered chemotherapeutics, a concept supported by preclinical and some clinical data.
• Ultrasound-Mediated Drug Delivery: Techniques like sonoporation use ultrasound waves and microbubble contrast agents to temporarily disrupt endothelial tight junctions or cell membranes via acoustic radiation force and cavitation, increasing local permeability for drugs or genes. This is being investigated for brain drug delivery (crossing the blood-brain barrier) and tumor treatment.

Off-Label and Investigational Applications

• FAK Inhibitors: Drugs like defactinib target focal adhesion kinase, a central node in mechanotransduction. They are being studied in cancers with a dense stroma (e.g., mesothelioma, pancreatic cancer) with the dual aim of disrupting cancer cell survival signals and potentially modulating the tumor mechanical microenvironment to improve drug access.
• Magnetic Drug Targeting: Iron oxide nanoparticles loaded with chemotherapeutic agents can be guided to a specific site (e.g., a tumor) using an externally applied magnetic field gradient, directly applying a physical force to overcome distribution barriers.
• Mechano-Responsive Biomaterials: Implantable scaffolds or injectable hydrogels designed to release drugs in response to specific mechanical cues, such as the increased shear stress at a site of vascular injury or the altered compression in an arthritic joint.

6. Adverse Effects

Adverse effects related to mechanopharmacology often arise from the unintended consequences of altering physical forces or from the off-target distribution of force-enabled delivery systems.

Common Side Effects

• Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia): A classic example seen with pegylated liposomal doxorubicin. The long-circulating nanoparticles eventually extravasate in capillaries of the hands and feet, which are subject to higher mechanical stress and possibly minor trauma. The subsequent local drug release causes tissue damage, redness, swelling, and pain. This is a direct result of the drug’s mechanopharmacokinetics—its distribution is influenced by regional microvascular dynamics and physical stress.
• Hypertension with VEGF Pathway Inhibitors: Drugs like bevacizumab inhibit vascular endothelial growth factor (VEGF), leading to vascular rarefaction and increased peripheral resistance. This adverse effect is a direct pharmacological alteration of vascular mechanics.
• Infusion-Related Reactions: For shear-sensitive formulations like certain lipid nanoparticles or microbubbles, the high shear stress in injection catheters or heart valves can cause premature drug release or particle aggregation, leading to acute reactions.

Serious/Rare Adverse Reactions

• Tumor Lysis Syndrome after Vascular Normalization: In theory, if a vascular-normalizing agent (e.g., an ARB) successfully improves tumor perfusion, it could lead to a sudden, massive delivery of a cytotoxic drug to a large volume of the tumor, precipitating severe tumor lysis syndrome.
• Accelerated Metastasis: Some matrix-remodeling agents, if not carefully controlled, could potentially degrade physical barriers that contain tumors, facilitating cancer cell invasion and metastasis. This risk has been a concern in the development of broad-spectrum matrix metalloproteinase (MMP) inhibitors.
• Off-Target Tissue Damage with Physical Force-Based Delivery: Ultrasound-mediated blood-brain barrier opening, if not precisely controlled, can cause unintended brain edema or hemorrhage due to excessive mechanical disruption. Magnetic targeting must be carefully calibrated to avoid trapping nanoparticles in healthy capillary beds.

7. Drug Interactions

Drug interactions in mechanopharmacology are often pharmacodynamic rather than metabolic, stemming from combined effects on the physical microenvironment.

Major Drug-Drug Interactions

Contraindications

Absolute contraindications specific to mechanopharmacological approaches are still being defined. However, relative contraindications may include:

• The use of long-circulating nanocarriers in patients with known capillary leak syndrome or severe inflammatory states, due to the risk of exacerbated tissue accumulation and toxicity.
• The application of focused ultrasound for drug delivery in areas with untreated vascular malformations or aneurysms, due to the risk of rupture.
• The use of aggressive matrix-depleting agents in cancers with a high risk of intravasation and metastasis without concurrent effective systemic therapy.

8. Special Considerations

Use in Pregnancy and Lactation

Data on most advanced mechanopharmacological strategies in pregnancy are nonexistent. Theoretical concerns are significant. Physical force-based methods (e.g., ultrasound, magnetic fields) could potentially affect fetal development, particularly during organogenesis. Nanoparticles may cross the placental barrier, the permeability of which is itself subject to mechanical and hemodynamic changes during pregnancy. Any therapy designed to alter vascular permeability or tissue mechanics is contraindicated unless the potential benefit overwhelmingly justifies the unknown fetal risk. Similarly, excretion into breast milk and the potential for nanoparticle accumulation in the infant are unknown and a source of concern.

Pediatric Considerations

Pediatric tissues have distinct mechanical properties—generally higher compliance and lower stiffness than adult tissues. The extracellular matrix composition and turnover are different. These factors could alter the distribution and efficacy of drugs, particularly nanomedicines or those relying on the EPR effect. Furthermore, developmental changes in hemodynamics and organ size require careful scaling of any physical force-based delivery parameters (e.g., ultrasound intensity, magnetic field strength). Growth plates are highly sensitive to mechanical load, and therapies affecting local mechanics near these structures must be used with extreme caution.

Geriatric Considerations

Aging is associated with progressive tissue stiffening (arteriosclerosis, fibrosis) and changes in vascular compliance. These alterations create a different baseline mechanical landscape for drug distribution. Increased vascular stiffness may lead to higher pulse pressures and altered shear stress patterns, potentially affecting endothelial function and the adhesion of targeted therapies. Reduced lymphatic function may enhance the EPR effect for nanomedicines but also increase the risk of edema. Age-related decline in renal and hepatic function must be considered alongside these mechanical changes when dosing any drug, especially those with a narrow therapeutic index.

Renal and Hepatic Impairment

Renal and hepatic impairments are not only states of altered metabolism and excretion but also of profoundly changed organ mechanics.

• Renal Impairment: Chronic kidney disease involves fibrosis, which increases tissue stiffness and interstitial pressure. Glomerular hypertension is a key mechanical insult in diabetic nephropathy. These changes can trap drugs in the interstitial space or alter their passage across the glomerular filter. Dosing of drugs cleared renally must account for reduced GFR, but the altered intranenal mechanics may also affect the pharmacodynamics of drugs acting on the kidney (e.g., the efficacy of an antifibrotic agent).
• Hepatic Impairment: Cirrhosis represents the endpoint of mechanopathological change in the liver, characterized by extreme stiffness (elasticity measurable by FibroScan®), portal hypertension, and altered hepatic blood flow. These forces directly impact drug pharmacokinetics: portal hypertension shunts blood away from hepatocytes, sinusoidal capillarization reduces endothelial fenestrations (affecting large molecule delivery), and ascites increases the volume of distribution for hydrophilic drugs. Dosing in liver impairment is complex because it must integrate both the biochemical (enzyme loss) and biophysical (altered flow and distribution) consequences of the disease.

9. Summary/Key Points

• Mechanopharmacology integrates the study of physical forces with pharmacology, providing a more complete understanding of drug delivery and action in the dynamic in vivo environment.
• Key physical forces include interstitial fluid pressure, solid stress, shear stress, and tissue stiffness. These forces are often pathologically elevated in conditions like solid tumors and fibrotic diseases, creating significant barriers to effective drug distribution.
• The cellular process of mechanotransduction links these physical cues to biochemical signaling (e.g., via FAK, Rho, YAP/TAZ), meaning the mechanical microenvironment can directly influence a cell’s susceptibility or resistance to drug therapy.
• Pharmacokinetics, especially distribution, is highly dependent on mechanical forces. Parameters like volume of distribution and clearance are not static but vary with physiological and pathological mechanical states.
• Existing therapeutic strategies, such as the use of pegylated liposomal doxorubicin, implicitly exploit mechanopharmacological principles (the EPR effect). Emerging strategies aim to actively modulate the mechanical microenvironment (e.g., with hyaluronidase) or use external forces (e.g., ultrasound, magnets) to direct drug delivery.
• Adverse effects, such as hand-foot syndrome from liposomal doxorubicin, can be direct consequences of a drug’s mechanopharmacokinetic profile. Drug interactions can occur when therapies combine to alter the physical microenvironment.
• Special populations (pediatric, geriatric, pregnant patients, those with renal/hepatic impairment) present unique mechanical landscapes that must be considered for safe and effective drug therapy, particularly for advanced delivery systems.

Clinical Pearls

• When a drug with proven efficacy in vitro fails in vivo, particularly in diseases like pancreatic cancer or glioblastoma, consider mechanical barriers to delivery (high IFP, dense stroma, blood-brain barrier) as a potential cause of therapeutic resistance.
• The variable efficacy of nanomedicines across patients and tumor types can often be attributed to heterogeneity in the tumor mechanical microenvironment, which affects the EPR effect.
• Non-invasive imaging techniques that measure tissue mechanics (e.g., elastography via MRI or ultrasound) may become valuable biomarkers in the future to stratify patients for mechanopharmacological therapies or to monitor their effects.
• Dosing regimens for drugs in patients with advanced organ fibrosis or edema may require adjustment beyond what is predicted by standard renal/hepatic function tests alone, due to concomitant changes in drug distribution volumes and access to target cells.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.